112889-02-8

Basic information

• Product Name: Diethyl N-[5-methylamino-2-thenoyl]-L-glutamate
• Synonyms: n-[[5-(methylamino)-2-thienyl]carbonyl]-l-glutamic acid diethyl ester;diethyl n-[5-methylamino-2-thenoyl]-l-glutamate;(S)-Diethyl 2-(5-(MethylaMino)thiophene-2-carboxaMido)pentanedioate
• CAS NO: 112889-02-8
• Molecular Formula: C₁₅H₂₂N₂O₅S
• Molecular Weight: 342.41
• Product Categories: Raltitrexed
• Mol File: 112889-02-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 519.647 °C at 760 mmHg
• Flash Point: 268.073 °C
• Appearance: /
• Density: 1.231
• Vapor Pressure: 6.7E-11mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.89±0.46(Predicted)
• CAS DataBase Reference: Diethyl N-[5-methylamino-2-thenoyl]-L-glutamate(CAS DataBase Reference)
• NIST Chemistry Reference: Diethyl N-[5-methylamino-2-thenoyl]-L-glutamate(112889-02-8)
• EPA Substance Registry System: Diethyl N-[5-methylamino-2-thenoyl]-L-glutamate(112889-02-8)

Safety Data

• Hazardous Substances Data: 112889-02-8(Hazardous Substances Data)

Usage

Uses

N-[[5-(Methylamino)-2-thienyl]carbonyl]-L-glutamic Acid Diethyl Ester can be used as reactant/reagent for synthetic preparation of Raltitrexed (anticancer agent). An intermediate or impurity in the synthesis of Raltitrexed (R100500). Raltitrexed (R100500) is folate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Antineoplastic.

InChI:InChI=1/C15H22N2O5S/c1-4-21-13(18)9-6-10(15(20)22-5-2)17-14(19)11-7-8-12(16-3)23-11/h7-8,10,16H,4-6,9H2,1-3H3,(H,17,19)/t10-/m0/s1

Upstream product

• 106585-63-1 N-(5-aminothiophene-2-carbonyl)-L-glutamic acid diethyl ester 
• 1094071-11-0 5-(N-tert-butoxycarbonyl)aminothiophene-2-carboxylic acid 
• 16450-41-2 L-glutamic acid diethyl ester 
• 67318-11-0 ethyl 2-amino-thiophene-5-carboxylate 
• 5751-84-8 5-nitro-2-thiophenecarboxylic acid ethyl ester 
• 527-72-0 2-thiophenylcarboxylic acid 
• 6317-37-9 5-nitrothiophene-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 
• 106585-64-2 N-(5-nitro-2-thiophenecarbonyl)-L-glutamic acid diethyl ester 
• 131052-68-1 5--2-thiophenecarboxylic acid 

Downstream Products

• 132463-02-6 N-[[5-[N-(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-N-methyl]amino-2-thiophenecarbonyl]-L-glutamic acid diethyl ester 
• 112887-68-0 N-[5-[N-[(3,4-dihydro-2-methyl-4-oxy-6-quinazolinyl)-methyl]-N-methylamino]-2-thenoyl]-L-glutamic acid 

Relevant articles and documents

Preparation method of raltitrexed

The invention belongs to the field of drug synthesis, and in particular, relates to a preparation method of raltitrexed. With an N-methylation reaction in the preparation method, the problems of longreaction time, more by-products and inconvenient post-treatment in a conventional method are overcome, and provided is new intermediate compounds represented by the formula IIIa and IVa. The N-methylation intermediate (compound represented by the formula IVa) and raltitrexed are rapidly prepared with high yield, high purity and fastness; the preparation method is simple in reaction operation and post-treatment, short in production cycle, good in reproducibility, mild in conditions, and suitable for industrial production.

Raltitrexed related substance C as well as preparation and application thereof

The invention discloses a raltitrexed related substance C with inhibition activity on dihydrofolate reductase and methionine synthetase, a preparation method and application thereof as an impurity control group.

Impurity A of raltitrexed, and preparation method and application thereof

The invention discloses a potential blood system toxic impurity A of raltitrexed, a preparation method thereof, and a use of the impurity A as an impurity reference substance.